Status:
COMPLETED
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Lead Sponsor:
Pfizer
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) w...
Detailed Description
The primary research question is to evaluate the apixaban utilization according to the approved SPAF indication and recommendations by EMA. In addition a comparison with a cohort of NVAF patients tre...
Eligibility Criteria
Inclusion
- Patients more than 18 years-old.
- Patients diagnosed with NVAF registered in primary care according to ICD-10.
- Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA experienced), dabigatran or rivaroxaban for the SPAF indication.
- Continuous enrolment in the 12 months pre-index.
Exclusion
- Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including patients with mitral prosthetic valves.
- Lost to follow-up (e.g. transfer to primary care center non-ICS).
Key Trial Info
Start Date :
February 18 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 8 2017
Estimated Enrollment :
51690 Patients enrolled
Trial Details
Trial ID
NCT03441633
Start Date
February 18 2016
End Date
March 8 2017
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IDIAP Jordi Gol
Barcelona, Catalonia, Spain, 8007